Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
80Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $62.38M | $-101.59M | $-0.87 |
| 2024 | $42.07M | $-130.30M | $-1.19 |
| 2023 | $36.53M | $-101.74M | $-1.08 |
| 2022 | $24.86M | $-108.18M | $-1.23 |
| 2021 | $37.04M | $-58.23M | $-0.94 |
Social Signal Score
Earnings
Tue, Nov 3(in 3 months)
Consensus estimate $-0.33 per share
Typical surprise -2.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.37 vs $-0.32miss
- Wed, May 13$-0.32 vs $-0.31miss
- Thu, Mar 5$-0.29 vs $-0.31beat
- Tue, Nov 4$0.13 vs $0.01beat
- Tue, Aug 5$-0.35 vs $-0.35beat
- Mon, May 12$-0.36 vs $-0.34miss
Estimates and results for TNGX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
TNGXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newszacks.com·3d ago·Negative
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.
View source ↗